Michael Nally - 26 Feb 2026 Form 4 Insider Report for Generate Biomedicines, Inc. (GENB)

Role: Chief Executive Officer, Director
Signature: /s/ Michael Wolf, Attorney-in-Fact
Issuer symbol: GENB
Transactions as of: 26 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 02 Mar 2026, 17:50:58 UTC
Previous filing: 15 Dec 2025
Next filing: 06 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Nally Michael	Chief Executive Officer, Director	GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE	/s/ Michael Wolf, Attorney-in-Fact	02 Mar 2026	0001763945

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GENB	Common Stock	Conversion of derivative security		+658,327	+100%		1,316,654	02 Mar 2026	By MTN 2024 GST Trust	F1, F2
holding	GENB	Common Stock						552,707	26 Feb 2026	Direct
holding	GENB	Common Stock						999,793	26 Feb 2026	By MTN 2024 GRAT	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GENB	Stock Option (Right to Buy)	Award	$0	+844,595		$0.000000	844,595	26 Feb 2026	Common Stock	844,595	$16.00	Direct	F3
transaction	GENB	Stock Option (Right to Buy)	Award	$0	+844,595		$0.000000	844,595	26 Feb 2026	Common Stock	844,595	$16.00	Direct	F4
transaction	GENB	Series A Preferred Stock	Conversion of derivative security	$0	-1,000,000	-100%	$0.000000	0	02 Mar 2026	Common Stock	658,327		By MTN 2024 GST Trust	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date.
F2	The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3	The shares underlying this option shall vest in two equal installments on each of February 19, 2029 and February 19, 2030, subject to the Reporting Person's continued service on each such vesting date.
F4	The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.